Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part …


Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

POPULAR TAGS

Novartis takes license on Celyad's allogeneic CAR T cells

Written by DS on in the category news with the tags , .


Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR T cells. This license agreement is related to two targets currently under development by Novartis.

Under the terms of the agreement Celyad receives an upfront payment and is eligible to receive success based clinical, regulatory and commercial milestone payments. If all success based milestones are achieved, Celyad is eligible to receive payments, including the upfront payment, totalling $96 million. In addition, Celyad will receive single digit royalties based on net sales of the licensed target associated products. Novartis has the option to extend the agreement to additional targets and/or to convert its license into an exclusive license. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR T cells.

Celyad will not be involved in the development of Novartis’ CAR T cells. Celyad will continue to focus on the development of its CAR T pipeline, including its allogeneic NKR-2 T cell immunotherapy in the EU and US territories and in collaboration with Ono Pharmaceuticals, its partner in Japan, Taiwan and Korea.
Christian Homsy, CEO of Celyad, said: “This non-exclusive agreement with Novartis recognizes the importance of our IP for companies developing allogeneic CAR T therapies”.

The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). The granted claims are not limited to specific CARs or specific methods of generating allogeneic CAR T cells, such as genome editing or genetic engineering.

Read more about: , .

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part …


Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation KU Leuven Turnstone GSK Janssen Itera Life Science Biowin V-Bio Ventures Flanders.bio UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.